Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

Delayed Quote. Delayed  - 05/22 07:26:53 pm
133.28 USD   +1.41%
05/18 INCYTE : Vaults on Drug Test Results
05/18 S&P 500 MOVERS : Csco, incy
05/18 NASDAQ 100 MOVE : Csco, incy
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on INCYTE CORPORATION
05/18 INCYTE : Vaults on Drug Test Results
05/18 S&P 500 MOVERS : Csco, incy
05/18 NASDAQ 100 MOVERS : Csco, incy
05/17 INCYTE : First Data from Combination of Epacadostat with Opdivo® (nivolumab) Wil..
05/17 INCYTE : New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Ep..
05/04 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
05/04 INCYTE : reports 1Q loss
05/04 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
05/04 INCYTE CORPORATION : Investor Network: Incyte Corporation to Host Earnings Call
05/04 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Results of Operations and Financ..
05/04 INCYTE : Reports 2017 First-Quarter Financial Results and Updates on Key Clinica..
05/04 INCYTE : reports strong revenue growth, loss for 1st quarter
04/25 INCYTE : to Present at Upcoming Investor Conferences
04/21 NASDAQ 100 MOVERS : Mat, incy
04/20 INCYTE : Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured ..
04/20 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporat..
04/19 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corpo..
04/18 INCYTE : to Report First Quarter Financial Results
04/18 INCYTE : FDA stuns Lilly and Incyte with CRL for much-anticipated RA drug barici..
04/18 Lilly and Incyte`s Loss Is AbbVie and Regeneron`s Gain
04/17 INCYTE CORPORATION : (INCY) Slides on FDA Nod
04/17 INCYTE CORP : Other Events (form 8-K)
04/15 ELI LILLY AND : Incyte Say FDA Issues CRL For Baricitinib
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
04/03 INCYTE : and Merck Provide Additional Details on Previously Announced Collaborat..
04/03 S&P 500 MOVERS : Hpe, incy
04/01 INCYTE : INCY) and Merck (MRK) Amplify Anti-tumor Collaboration
03/10 INCYTE : Financial Statements and Exhibits (form 8-K/A)
03/09 INCYTE : Raises Awareness for Myeloproliferative Neoplasms as Part of Rare Disea..
03/09 INCYTE : Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abs..
03/09 Bull market turns 8 - historical facts and figures
03/06DJINCYTE : Race Tightens for Next Wave of Cancer Drugs
03/02 INCYTE : Announces Oncology Research Alliance with the Abramson Cancer Center at..
03/02 INCYTE : Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abs..
02/28 INCYTE : Raises Awareness for Myeloproliferative Neoplasms as Part of Rare Disea..
02/26 INCYTE : announces collaboration with Penn cancer center
02/24 NASDAQ 100 MOVERS : Bidu, incy
02/24 INCYTE : and Agenus Amend Collaboration Agreement
02/24 ELI LILLY AND : European Commission Approves Once-Daily Olumiant Tablets for Tre..
02/24 ELI LILLY AND : Additional results from pivotal RA-BEAM study published in New E..
02/23 INCYTE : Announces Oncology Research Alliance with the Abramson Cancer Center at..
02/23 INCYTE : University of Pennsylvania Announces Cancer Research Alliance with Incy..
02/21 INCYTE : to Present at Upcoming Investor Conferences
02/21 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Entry into a Material Definitive..
02/21 INCYTE CORP : Entry into a Material Definitive Agreement, Unregistered Sale of E..
02/16 ELI LILLY AND : EC approves Eli Lilly's rheumatoid arthritis drug
02/15 INCYTE : Additional results from pivotal RA-BEAM study published in New England ..
02/15 AGENUS INC. (NASDAQ : AGEN) Files An 8-K Entry into a Material Definitive Agreem..
02/15 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Results of Operations and Financ..
02/15 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Entry into a Material Definitive..
02/14 INCYTE CORP : Entry into a Material Definitive Agreement, Regulation FD Disclosu..
02/14 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
02/14 NETWORKNEWSBREAKS – AMENDED CO : AGEN), Incyte Corp. (NASDAQ: INCY) Shares..
02/14 INCYTE : INCY) Gains on Agenus Deal
02/14 NASDAQ 100 MOVERS : Logm, incy
02/14 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
02/14 INCYTE : tops Street 4Q forecasts
02/14 INCYTE : Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 20..
02/13 ELI LILLY AND : European Commission Approves Once-Daily Olumiant Tablets for Tre..
02/13 INCYTE : NICE approves Incyte’s leukaemia drug for routine NHS use
02/09 INCYTE : and Calithera Biosciences Announce Global Collaboration to Develop and ..
02/09INCYTE CORPORATION : annual earnings release
02/06 IMMUNOVACCINE : IMV; IMMVF) Lead Immuno-Oncology Candidate to Enter Investigator..
01/31 CALITHERA BIOSCIENCES INC (NASDAQ : CALA): What You Need To Know
01/31 INCYTE : and Calithera Biosciences Announce Global Collaboration to Develop and ..
01/31 CALITHERA BIOSCIENCES, INC. (NASDAQ : CALA) Files An 8-K Entry into a Material D..
01/30 INCYTE : strikes drug development deal with California company
01/25 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Other Events
01/24 INCYTE : to Report Fourth Quarter and Year-End Financial Results
01/23 INCYTE CORP : Other Events (form 8-K)
01/19 INCYTE : and Merck to Advance Clinical Development Program Investigating the Com..
01/19 INCYTE : Studies from Incyte Add New Findings in the Area of Pharmacokinetics (P..
01/17 NASDAQ 100 MOVERS : Incy, dltr
01/16 ELI LILLY AND : FDA extends review period for Eli Lilly's rheumatoid arthritis d..
1  2  3  4  5  6Next
Advertisement
Financials ($)
Sales 2017 1 428 M
EBIT 2017 -64,7 M
Net income 2017 -134 M
Finance 2017 268 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 333,41
EV / Sales 2017 18,7x
EV / Sales 2018 16,2x
Capitalization 26 914 M
More Financials
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 145 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Senior Vice President
Paul Alan Brooke Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION31.08%26 914
QUINTILES IMS HOLDINGS..9.20%18 274
LONZA GROUP AG18.67%15 134
CELLTRION, INC.--.--%10 399
SEATTLE GENETICS, INC.26.21%9 505
ALKERMES PLC4.19%8 871
More Results